Electronic Acknowledgement Receipt					
EFS ID:	7591313				
Application Number:	10016604				
International Application Number:					
Confirmation Number:	6543				
Title of invention:	ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER				
First Named Inventor/Applicant Name:	Pablo D. Garcia				
Customer Number:	27476				
Filer:	Benjamin Claude Spehlmann/Sandra Ferony				
Filer Authorized By:	Benjamin Claude Spehlmann				
Attorney Docket Number:	PAT051489-US-NP				
Receipt Date:	11-MAY-2010				
Filing Date:	07-DEC-2001				
Time Stamp:	16:45:33				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	3234
Deposit Account	190733
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Supplemental312Amendment.	69499		4
'	pdf	1947c8aaaaed8fc55dd13cf853dc62050d1b 44f3	yes	4	
	Multip	oart Description/PDF files in .	zip description		
	Document Description		Start	End	
	Amendment after Notice of Allowance (Rule 312)		1	2	
	Applicant Arguments/Remarks Made in an Amendment		3	4	
Warnings:					
Information:					
2	2 Transmittal Letter	SupplementallDS.pdf	769323	no	4
			5381c2x839860e5382642/909be0226e1f3 c3c2		
Warnings:					
Information:					
3	3 NPL Documents	OfficeAction.pdf	596106	no	17
,	W E Documents		SSRidbbr954S1a4e2ebSeeaff50167aa018d 6dd8		
Warnings:					
Information:					
4 NPL Documents	Seher EMBL Gen Bank Database. pdf	58631	no	2	
		446b711cbe0f5e93ed80951lb8d410b44e6 9db3e			
Warnings:					
Information:					
5 Fee Worksheet (PTO-875)	fee-info.pdf	30390	no	2	
		Se3ald6265036537F9460de3c541sSlc7aef0c ebe			
Warnings:					
Information:					
		Total Files Size (in bytes)	15	23949	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-[d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.